Fresenius SE & Co KGaA (FRE.DE) Stock Price

Fresenius SE & Co KGaA Price

🇩🇪XETRA·CLOSED
37.67EUR
Market closed
Today +/-
Today %

Fresenius SE & Co KGaA (FRE.DE) Stock | ISIN DE0005785604 | WKN 578560. The current Fresenius SE & Co KGaA stock price is 37.67 EUR (2026). Revenue is 23.9 B EUR. Net income is 2.1 B EUR. The P/E ratio is 10.13. Market capitalization is 21.26 B EUR. Fresenius SE & Co KGaA operates in the Health sector.

Fresenius SE & Co KGaA stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Fresenius SE & Co KGaA over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Fresenius SE & Co KGaA stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Fresenius SE & Co KGaA's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Fresenius SE & Co KGaA Stock Price History
DateFresenius SE & Co KGaA Price
Access this data via the Eulerpool API
Get Free API Key

Fresenius SE & Co KGaA Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
10.78 B EUR
1.44 B EUR
330 M EUR
Jan 1, 2007
11.39 B EUR
1.65 B EUR
422 M EUR
Jan 1, 2008
12.35 B EUR
1.76 B EUR
528 M EUR
Jan 1, 2009
14.17 B EUR
2.05 B EUR
475 M EUR
Jan 1, 2010
15.97 B EUR
2.42 B EUR
619 M EUR
Jan 1, 2011
16.52 B EUR
2.56 B EUR
690 M EUR
Jan 1, 2012
19.51 B EUR
2.99 B EUR
930 M EUR
Jan 1, 2013
20.55 B EUR
2.99 B EUR
988 M EUR
Jan 1, 2014
23.46 B EUR
3.12 B EUR
1.07 B EUR
Jan 1, 2015
28 B EUR
3.94 B EUR
1.39 B EUR
Jan 1, 2016
29.47 B EUR
4.33 B EUR
1.56 B EUR
Jan 1, 2017
33.89 B EUR
4.56 B EUR
1.81 B EUR
Jan 1, 2018
33.53 B EUR
4.45 B EUR
2.03 B EUR
Jan 1, 2019
35.41 B EUR
4.63 B EUR
1.88 B EUR
Jan 1, 2020
36.28 B EUR
4.36 B EUR
1.71 B EUR

Fresenius SE & Co KGaA Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 10, 2026, 12:35 PM
 
REVENUE (M EUR)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M EUR)
NET INCOME (M EUR)
NET INCOME GROWTH (%)
DIV. (EUR)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Fresenius SE & Co KGaA generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Fresenius SE & Co KGaA retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Fresenius SE & Co KGaA's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Fresenius SE & Co KGaA has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Fresenius SE & Co KGaA's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Fresenius SE & Co KGaA stock margins

The Fresenius SE & Co KGaA margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fresenius SE & Co KGaA. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fresenius SE & Co KGaA.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
31.89 %
13.39 %
3.06 %
Jan 1, 2007
32.52 %
14.46 %
3.7 %
Jan 1, 2008
31.92 %
14.25 %
4.27 %
Jan 1, 2009
32.79 %
14.47 %
3.35 %
Jan 1, 2010
33.33 %
15.17 %
3.88 %
Jan 1, 2011
34.13 %
15.51 %
4.18 %
Jan 1, 2012
33.37 %
15.32 %
4.77 %
Jan 1, 2013
32.13 %
14.55 %
4.81 %
Jan 1, 2014
30.15 %
13.3 %
4.56 %
Jan 1, 2015
31.87 %
14.08 %
4.95 %
Jan 1, 2016
32.28 %
14.69 %
5.29 %
Jan 1, 2017
30.96 %
13.47 %
5.35 %
Jan 1, 2018
29.33 %
13.27 %
6.05 %
Jan 1, 2019
29.22 %
13.07 %
5.32 %
Jan 1, 2020
28.44 %
12.02 %
4.71 %

Fresenius SE & Co KGaA Stock Revenue, EBIT, Earnings per Share

The Fresenius SE & Co KGaA earnings per share therefore indicates how much revenue Fresenius SE & Co KGaA has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
23.22 EUR
3.11 EUR
0.71 EUR
Jan 1, 2007
24.29 EUR
3.51 EUR
0.9 EUR
Jan 1, 2008
25.9 EUR
3.69 EUR
1.11 EUR
Jan 1, 2009
29.21 EUR
4.23 EUR
0.98 EUR
Jan 1, 2010
32.73 EUR
4.97 EUR
1.27 EUR
Jan 1, 2011
33.51 EUR
5.2 EUR
1.4 EUR
Jan 1, 2012
37.23 EUR
5.7 EUR
1.77 EUR
Jan 1, 2013
38.05 EUR
5.54 EUR
1.83 EUR
Jan 1, 2014
43.1 EUR
5.73 EUR
1.97 EUR
Jan 1, 2015
51.07 EUR
7.19 EUR
2.53 EUR
Jan 1, 2016
53.58 EUR
7.87 EUR
2.84 EUR
Jan 1, 2017
60.78 EUR
8.18 EUR
3.25 EUR
Jan 1, 2018
60.16 EUR
7.98 EUR
3.64 EUR
Jan 1, 2019
63.52 EUR
8.3 EUR
3.38 EUR
Jan 1, 2020
65.04 EUR
7.82 EUR
3.06 EUR

Fresenius SE & Co KGaA business model & stock analysis

Fresenius SE is a German pharmaceutical and medical technology company, which was founded in 1912 by Eduard Fresenius. The company's history is marked by continuous growth and numerous acquisitions, which have shaped the current corporate structure. Fresenius operates in four different divisions: Fresenius Medical Care is a global leader in dialysis treatment and offers products as well as services related to dialysis. Fresenius Kabi specializes in the production of medications and medical devices for infusion and nutrition therapy. Fresenius Helios is one of the largest providers of hospital treatments with over 110 clinics and operates facilities in Germany, Spain, and Latin America. Fresenius Vamed offers services related to the management and planning of healthcare facilities and operates worldwide in over 85 countries. The business model of Fresenius SE is based on the development and production of innovative medical products, as well as the provision of services in the healthcare sector. The company relies on high-quality products and intensive research and development. A key factor for success is focusing on the needs of customers and patients to ensure the best possible care. One of the most well-known products of Fresenius SE are the Fresenius concentrates for dialysis treatment. These enable effective and gentle blood cleansing, thereby improving the quality of life for dialysis patients. Another example of innovative products are the 3-in-1 infusion systems by Fresenius Kabi. These combine the administration of fluids, medications, and nutrition into one system, offering significantly higher efficiency in patient care. Fresenius Helios focuses on patient-centered care and offers a wide range of medical services. The company operates both acute care clinics and long-term care facilities and utilizes state-of-the-art technologies to improve diagnosis and treatment. Fresenius Vamed provides its customers with services such as facility management, planning, and project management for healthcare facilities, as well as operational consulting. The comprehensive expertise in all areas of the healthcare industry ensures high quality in the implementation of construction projects and renovations. In summary, Fresenius SE is an internationally active company specializing in the provision of high-quality products and services in the healthcare sector. The company focuses on patient-centered care and the continuous development of innovative products and technologies.

Fresenius SE & Co KGaA SWOT Analysis

Strengths

Fresenius SE possesses several key strengths:

  • Established presence and reputation in the healthcare industry
  • Diversified product portfolio spanning pharmaceuticals, medical devices, and services
  • Strong financial performance and stability
  • Global operations and strong market position
  • Strong research and development capabilities

Weaknesses

Despite its overall strength, Fresenius SE also faces certain weaknesses:

  • Dependency on third-party suppliers for key components
  • Regulatory challenges in different markets
  • Relatively high debt levels
  • Competitive pressures in the healthcare industry

Opportunities

Fresenius SE can capitalize on the following opportunities:

  • Increasing demand for healthcare products and services, driven by aging population and emerging markets
  • Expanding its product portfolio through strategic acquisitions and partnerships
  • Advancements in technology opening up new possibilities for product innovation
  • Expanding into underserved or untapped markets

Threats

Fresenius SE must be cautious of the following potential threats:

  • Intense competition from global and local players
  • Changing regulatory frameworks and compliance requirements
  • Volatility in raw material prices
  • Economic downturns impacting healthcare spending

Fresenius SE & Co KGaA Eulerpool Fair Value

Fresenius SE & Co KGaA historical P/E ratio, EBIT multiple, and P/S ratio

Fresenius SE & Co KGaA annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Fresenius SE & Co KGaA shares outstanding

The number of shares was Fresenius SE & Co KGaA in 2025 — This indicates how many shares 564.286 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
464 M base_Shares
Jan 1, 2007
469 M base_Shares
Jan 1, 2008
477 M base_Shares
Jan 1, 2009
485 M base_Shares
Jan 1, 2010
488 M base_Shares
Jan 1, 2011
493 M base_Shares
Jan 1, 2012
524 M base_Shares
Jan 1, 2013
540 M base_Shares
Jan 1, 2014
544.3 M base_Shares
Jan 1, 2015
548.16 M base_Shares
Jan 1, 2016
550.08 M base_Shares
Jan 1, 2017
557.51 M base_Shares
Jan 1, 2018
557.3 M base_Shares
Jan 1, 2019
557.42 M base_Shares
Jan 1, 2020
557.74 M base_Shares

Fresenius SE & Co KGaA Dividend History

27 years of dividend payments · 2 consecutive increases

YearAnnual DividendYoY ChangePayments
20261.05EURYTD—1×
May 25, 20261.05EUR↑ 5.0%1/1
20251EUR↑ 8.7%1×
May 26, 20251EUR↑ 8.7%1/1
20230.92EUR↑ 39.4%1×
20220.66EUR↓ 62.5%1×
20211.76EUR↑ 109.5%2×
20200.84EUR↑ 5.0%1×
20190.8EUR↑ 6.7%1×
20180.75EUR↑ 21.0%1×
20170.62EUR↑ 12.7%1×
20160.55EUR↑ 25.0%1×

Fresenius SE & Co KGaA dividend history and estimates

In 2025, Fresenius SE & Co KGaA paid a dividend amounting to 1 EUR. Dividend means that Fresenius SE & Co KGaA distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2006
1.48 EUR
0 EUR
0 EUR
Jan 1, 2007
0.57 EUR
0 EUR
0 EUR
Jan 1, 2008
0.66 EUR
0 EUR
0 EUR
Jan 1, 2009
0.7 EUR
0 EUR
0 EUR
Jan 1, 2010
0.75 EUR
0 EUR
0 EUR
Jan 1, 2011
0.86 EUR
0 EUR
0 EUR
Jan 1, 2012
1.9 EUR
0 EUR
0 EUR
Jan 1, 2013
1.1 EUR
0 EUR
0 EUR
Jan 1, 2014
1.25 EUR
0 EUR
0 EUR
Jan 1, 2015
0.44 EUR
0 EUR
0 EUR
Jan 1, 2016
0.55 EUR
0 EUR
0 EUR
Jan 1, 2017
0.62 EUR
0 EUR
0 EUR
Jan 1, 2018
0.75 EUR
0 EUR
0 EUR
Jan 1, 2019
0.8 EUR
0 EUR
0 EUR
Jan 1, 2020
0.84 EUR
0 EUR
0 EUR

Fresenius SE & Co KGaA dividend payout ratio

In 2025, Fresenius SE & Co KGaA had a payout ratio of 34.1%. The payout ratio indicates the percentage of the company's profits that Fresenius SE & Co KGaA distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
23.15 %
Jan 1, 2007
21.11 %
Jan 1, 2008
20 %
Jan 1, 2009
23.81 %
Jan 1, 2010
20 %
Jan 1, 2011
20.63 %
Jan 1, 2012
35.79 %
Jan 1, 2013
20.04 %
Jan 1, 2014
21.2 %
Jan 1, 2015
17.41 %
Jan 1, 2016
19.39 %
Jan 1, 2017
19.05 %
Jan 1, 2018
20.62 %
Jan 1, 2019
23.68 %
Jan 1, 2020
27.45 %
Price targets and forecasts for Fresenius SE & Co KGaA are not yet available.

Fresenius SE & Co KGaA Earnings Estimates

Fresenius SE & Co KGaA Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
2/20/20240.84EUR7.7 BEUR2023 Q4
11/1/20220.71EUR10.5 BEUR2022 Q3
7/27/20220.83EUR10.1 BEUR2022 Q2
5/4/20220.79EUR9.57 BEUR2022 Q1
2/22/20220.89EUR10.02 BEUR2021 Q4
11/2/20210.77EUR9.41 BEUR2021 Q3
7/30/20210.81EUR9.19 BEUR2021 Q2
5/6/20210.78EUR9.07 BEUR2021 Q1
2/23/20210.9EUR9.28 BEUR2020 Q4
10/29/20200.77EUR9.04 BEUR2020 Q3

EESG©

Eulerpool ESG Scorecard© for the Fresenius SE & Co KGaA stock

83/100
78
Environment
99
Social
72
Governance
E

Environment

20
Scope 1 - Direct Emissions351,128
Scope 2 - Indirect emissions from purchased energy447,563
Scope 3 - Indirect emissions within the value chain3,683,377
Total CO₂ emissions798,691
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees67.358
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Fresenius SE & Co KGaA shareholder structure

% Name
26.94983%
Else Kroner-Fresenius Foundation
Else Kroner-Fresenius Foundation
4.97276%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.51518%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
3.03767%
Capital Research Global Investors
Capital Research Global Investors
2.43548%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
2.16807%
DWS Investment GmbH
DWS Investment GmbH
1.4856%
Deka Investment GmbH
Deka Investment GmbH
1.48285%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
1.08113%
Eleva Capital SAS
Eleva Capital SAS
0.92847%
Harris Associates L.P.
Harris Associates L.P.
...

Fresenius SE & Co KGaA Executives and Management Board

MS

Mr. Michael Sen

(56)

Chairman of the Management Board

Compensation4.44 M EUR
PA

Mr. Pierluigi Antonelli

(62)

Member of the Management Board, Chief Executive Officer - Fresenius Kabi

Compensation2.35 M EUR
SH

Ms. Sara Hennicken

(44)

Chief Financial Officer, Member of the Management Board

Compensation2.08 M EUR
RM

Mr. Robert Moeller

(57)

Member of the Management Board, Chief Executive Officer of Fresenius Helios

Compensation1.99 M EUR
MM

Mr. Michael Moser

(49)

Member of the Management Board, Responsible for Legal, Compliance, Risk Management, ESG, Human Resources, Corporate Audit and Fresenius Vamed

Compensation1.87 M EUR

Fresenius SE & Co KGaA Supply Chain

Frequently asked questions about Fresenius SE & Co KGaA

Fresenius SE is a German healthcare company specializing in the provision of medical products and services. The company's business model focuses on four main segments: Fresenius Medical Care, a global leader in dialysis treatment and services; Fresenius Kabi, offering essential medicines and clinical nutrition products; Fresenius Helios, providing high-quality hospital and healthcare services; and Fresenius Vamed, specializing in projects and services for healthcare facilities. Through these segments, Fresenius SE aims to contribute to the improvement of patients' quality of life, offering comprehensive and innovative healthcare solutions worldwide.

All fundamentals and in-depth analysis of Fresenius SE & Co KGaA

Our stock analysis for Fresenius SE & Co KGaA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fresenius SE & Co KGaA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Revenue→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Net Income→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA P/E→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA P/S→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA EBIT→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Dividend→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Directors Dealings→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Stocks→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Market capitalization→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Debt→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Liabilities→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Equity→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA AAQS→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA Employees→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA ROE→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA ROA→
Fresenius SE & Co KGaA Stock
Fresenius SE & Co KGaA ROCE→